Abstract
Pranlukast, a specific cysteinyl leukotriene receptor antagonist, has been shown to have a action of bronchodilataion in a short time. This study was undertaken to compare the utility of pranlukast with sustained release theophylline product in the initial treatment period of exacerbation of bronchial asthma in childhood.
Sixty asthmatic children who have suffered attacks for two weeks or more, were enrolled to receive pranlukast (7mmg/kg) or sustained release theophylline product (10mg/kg) in a randomized fashion. They were observed for the observation period of two weeks and administering period of 4 weeks to document the effects on the attack score and the QOL score.
The attack score of pranlukast group was gradually improved better than that of sustained release theophylline statistically in less than 4 years old. The QOL score of both groups decreased in the same way.
Therefore, compared with sustained release theophylline, pranlukast is more useful in the initial treatment period of exacerbation of bronchial asthma in childhood.
